iCo Therapeutics in licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B Amp B as the initial platform candidate, utilizing a known anti fungal drug to treat life threatening infectious diseases. iCo also has worldwide rights to iCo , a monoclonal antibody targeting eotaxin . With Phase clinical history, Bertilimumab iCo is candidate for the treatment of vernal or atopic keratoconjunctivitis. iCo is in Phase clinical studies with iCo s partner, Immune Pharmaceuticals.
Quote | Ico Therapeutics Inc (OTCMKTS:ICOTF)
Last: | $0.9387 |
---|---|
Change Percent: | -1.29% |
Open: | $0.938 |
Close: | $0.9387 |
High: | $0.9387 |
Low: | $0.938 |
Volume: | 5,250 |
Last Trade Date Time: | 12/09/2021 04:54:28 pm |
News | Ico Therapeutics Inc (OTCMKTS:ICOTF)
Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...
Satellos Bioscience Inc Ordinary Shares (ICOTF) is expected to report for Q3 2023
Message Board Posts | Ico Therapeutics Inc (OTCMKTS:ICOTF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Ico Therapeutics Inc Company Name:
ICOTF Stock Symbol:
OTCMKTS Market:
Ico Therapeutics Inc Website:
Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...
Satellos Bioscience Inc Ordinary Shares (ICOTF) is expected to report for Q3 2023
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in ...